American Society of Hematology

Figure 1.

$Figure 1. Unique expression of CCR9 and CD103 on the leukemic cells of patient 7125. Multicolor flow cytometry was carried out on a peripheral blood sample obtained at diagnosis using a panel of chemokine receptor- and homing molecule-specific antibodies in combination with markers for T cells. (A) The unique expression of CCR9 and CD103 on the blast cells from patient 7125 is shown (top panel). The bottom panel shows a representative result for expression of these same receptors as found on T cells of 10 other T-ALL patients. Open histograms indicate level of control staining; red histograms, specific staining. Brackets and percentages denote the fraction of antibody-positive cells. (B) Immunohistochemistry was performed on the tumor cell infiltrate in the ileum of patient 7125. Using an anti-CCR9 polyclonal antibody and DAB detection (brown) there was clear positivity of the tumor cells for CCR9. The specificity of the CCR9 staining was confirmed by omitting the CCR9 antibody as a negative control. Furthermore, immunohistochemical staining using an anti-CCL25/TECK monoclonal antibody and NovaRed detection revealed a high expression of this CCR9 ligand in the tumor mass. The lower right picture shows hematoxylin and eosin (H+E) staining of the same area of the affected ileum at relapse. Original magnification, × 250.$

Unique expression of CCR9 and CD103 on the leukemic cells of patient 7125. Multicolor flow cytometry was carried out on a peripheral blood sample obtained at diagnosis using a panel of chemokine receptor- and homing molecule-specific antibodies in combination with markers for T cells. (A) The unique expression of CCR9 and CD103 on the blast cells from patient 7125 is shown (top panel). The bottom panel shows a representative result for expression of these same receptors as found on T cells of 10 other T-ALL patients. Open histograms indicate level of control staining; red histograms, specific staining. Brackets and percentages denote the fraction of antibody-positive cells. (B) Immunohistochemistry was performed on the tumor cell infiltrate in the ileum of patient 7125. Using an anti-CCR9 polyclonal antibody and DAB detection (brown) there was clear positivity of the tumor cells for CCR9. The specificity of the CCR9 staining was confirmed by omitting the CCR9 antibody as a negative control. Furthermore, immunohistochemical staining using an anti-CCL25/TECK monoclonal antibody and NovaRed detection revealed a high expression of this CCR9 ligand in the tumor mass. The lower right picture shows hematoxylin and eosin (H+E) staining of the same area of the affected ileum at relapse. Original magnification, × 250.

This Feature Is Available To Subscribers Only